Cargando…

Updated Insights on EGFR Signaling Pathways in Glioma

Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma is better understood. For the newly diagnosed, the current standard of care is represented by resection followed by radiotherapy and temozolomide administration, but because median overall survival remains poor,...

Descripción completa

Detalles Bibliográficos
Autores principales: Oprita, Alexandru, Baloi, Stefania-Carina, Staicu, Georgiana-Adeline, Alexandru, Oana, Tache, Daniela Elise, Danoiu, Suzana, Micu, Elena Simona, Sevastre, Ani-Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827907/
https://www.ncbi.nlm.nih.gov/pubmed/33435537
http://dx.doi.org/10.3390/ijms22020587
_version_ 1783640881521229824
author Oprita, Alexandru
Baloi, Stefania-Carina
Staicu, Georgiana-Adeline
Alexandru, Oana
Tache, Daniela Elise
Danoiu, Suzana
Micu, Elena Simona
Sevastre, Ani-Simona
author_facet Oprita, Alexandru
Baloi, Stefania-Carina
Staicu, Georgiana-Adeline
Alexandru, Oana
Tache, Daniela Elise
Danoiu, Suzana
Micu, Elena Simona
Sevastre, Ani-Simona
author_sort Oprita, Alexandru
collection PubMed
description Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma is better understood. For the newly diagnosed, the current standard of care is represented by resection followed by radiotherapy and temozolomide administration, but because median overall survival remains poor, new diagnosis and treatment strategies are needed. Due to the quick progression, even with aggressive multimodal treatment, glioblastoma remains almost incurable. It is known that epidermal growth factor receptor (EGFR) amplification is a characteristic of the classical subtype of glioma. However, targeted therapies against this type of receptor have not yet shown a clear clinical benefit. Many factors contribute to resistance, such as ineffective blood–brain barrier penetration, heterogeneity, mutations, as well as compensatory signaling pathways. A better understanding of the EGFR signaling network, and its interrelations with other pathways, are essential to clarify the mechanisms of resistance and create better therapeutic agents.
format Online
Article
Text
id pubmed-7827907
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78279072021-01-25 Updated Insights on EGFR Signaling Pathways in Glioma Oprita, Alexandru Baloi, Stefania-Carina Staicu, Georgiana-Adeline Alexandru, Oana Tache, Daniela Elise Danoiu, Suzana Micu, Elena Simona Sevastre, Ani-Simona Int J Mol Sci Review Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma is better understood. For the newly diagnosed, the current standard of care is represented by resection followed by radiotherapy and temozolomide administration, but because median overall survival remains poor, new diagnosis and treatment strategies are needed. Due to the quick progression, even with aggressive multimodal treatment, glioblastoma remains almost incurable. It is known that epidermal growth factor receptor (EGFR) amplification is a characteristic of the classical subtype of glioma. However, targeted therapies against this type of receptor have not yet shown a clear clinical benefit. Many factors contribute to resistance, such as ineffective blood–brain barrier penetration, heterogeneity, mutations, as well as compensatory signaling pathways. A better understanding of the EGFR signaling network, and its interrelations with other pathways, are essential to clarify the mechanisms of resistance and create better therapeutic agents. MDPI 2021-01-08 /pmc/articles/PMC7827907/ /pubmed/33435537 http://dx.doi.org/10.3390/ijms22020587 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Oprita, Alexandru
Baloi, Stefania-Carina
Staicu, Georgiana-Adeline
Alexandru, Oana
Tache, Daniela Elise
Danoiu, Suzana
Micu, Elena Simona
Sevastre, Ani-Simona
Updated Insights on EGFR Signaling Pathways in Glioma
title Updated Insights on EGFR Signaling Pathways in Glioma
title_full Updated Insights on EGFR Signaling Pathways in Glioma
title_fullStr Updated Insights on EGFR Signaling Pathways in Glioma
title_full_unstemmed Updated Insights on EGFR Signaling Pathways in Glioma
title_short Updated Insights on EGFR Signaling Pathways in Glioma
title_sort updated insights on egfr signaling pathways in glioma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827907/
https://www.ncbi.nlm.nih.gov/pubmed/33435537
http://dx.doi.org/10.3390/ijms22020587
work_keys_str_mv AT opritaalexandru updatedinsightsonegfrsignalingpathwaysinglioma
AT baloistefaniacarina updatedinsightsonegfrsignalingpathwaysinglioma
AT staicugeorgianaadeline updatedinsightsonegfrsignalingpathwaysinglioma
AT alexandruoana updatedinsightsonegfrsignalingpathwaysinglioma
AT tachedanielaelise updatedinsightsonegfrsignalingpathwaysinglioma
AT danoiusuzana updatedinsightsonegfrsignalingpathwaysinglioma
AT micuelenasimona updatedinsightsonegfrsignalingpathwaysinglioma
AT sevastreanisimona updatedinsightsonegfrsignalingpathwaysinglioma